Press Releases

WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and

- 55% overall response rate and 24% CR/CRh rate in relapsed/refractory acute leukemia patients with NPM1 or MLLr mutations; no discontinuations due to treatment-related adverse events - - CR/CRh rates of 23% and 24% in mNPM1 and MLLr patients, respectively - - CR/CRh responses were durable; median

- 68% overall response rate and broad multiorgan clinical benefit observed in highly refractory patients treated at doses being assessed in ongoing AGAVE-201 pivotal study - - Axatilimab well-tolerated at all doses and schedules - WALTHAM, Mass. , Dec.

WALTHAM, Mass. , Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to

- Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias - - Entered global collaboration with Incyte to develop and commercialize axatilimab for cGVHD and other fibrotic diseases - - Updated data from SNDX-5613 and axatilimab clinical

WALTHAM, Mass. , Nov. 8, 2021 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial

- Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 portion of AUGMENT-101 trial of SNDX-5613 in relapsed or refractory patients with genetically-defined acute leukemias - - Phase 2 results highlight broad efficacy

- Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with potential for $450 million in additional milestone payments; 50:50 profit share in the U.S. and double-digit royalties on ex-U.S. sales - - The two companies expect to expand development of

WALTHAM, Mass. , Sept. 15, 2021 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members

WALTHAM, Mass. , Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in

- Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated results from Phase 1 portion anticipated in 4Q21 - - Syndax initiating frontline combination of SNDX-5613 with venetoclax and azacitidine in the Beat®

WALTHAM, Mass. , Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2021 financial